April 2009
Worldwide Biotech;Apr2009, Vol. 21 Issue 4, p1
Trade Publication
The article reports on data from the Satraplatin and Prednisone Against Refractory Cancer (SPARC) double-blind, randomized satraplatin Phase 3 trial by GPC Biotech AG. The data, presented at the 2009 American Society for Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida, showed a positive trend toward better overall survival for the patients treated with satraplatin. According to physician Daniel Petrylak, the results point out the need for additional testing in trials in docetaxel-refractory CRPC patient populations.


Related Articles

  • GPC Biotech reports positive data from Phase III cancer trial.  // PharmaWatch: Cancer;Apr2009, Vol. 8 Issue 4, p15 

    The article focuses on the significance of the Sparc trial conducted by the GPC Biotech AG. As stated, the Sparc trial evaluated satraplatin plus prednisone versus placebo plus prednisone in 950 patients with androgen-independent or castraterefractory prostate cancer (CRPC) who had passed after...

  • SATRAPLATIN SPARC PHASE 3 PROSTATE CANCER DATA REPORTED.  // Worldwide Biotech;Jul2008, Vol. 20 Issue 7, p5 

    The article details the survival results of the Phase 3 SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) conducted by GPC Biotech AG. The company presented the clinical trial results at the 44th Annual Meeting of the American Society for Clinical Oncology in Chicago, Illinois....

  • 'Major Setback' As Satraplatin Fails To Improve Overall Survival. Boggs, Jennifer // BioWorld Today;11/1/2007, Vol. 18 Issue 213, p1 

    The article reports on the failure of GPC Biotech AG to reach the overall survival endpoint of its Phase III Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial. According to the overall survival data, patients in the satraplatin group had a median overall survival of 61.3 weeks...

  • GPC Biotech receives clearance from FDA to begin phase III registrational trial of satraplatin.  // PharmaWatch: Cancer;October 2003, Vol. 2 Issue 10, p13 

    Reports that GPC Biotech AG has received written confirmation from the United States Food and Drug Administration (FDA) that the company may initiate a phase III registrational trial with satraplatin plus prednisone in patients with hormone-refractory prostate cancer who have failed prior...

  • Phase Report.  // Applied Clinical Trials;Aug2007, Vol. 16 Issue 8, p20 

    The article offers news briefs related to drug clinical trials. GPC Biotech AG and Pharmion Corp. have presented positive results from their Phase III trials evaluating the efficacy of satraplatin plus prednisone. Cytos Biotechnology AG has announced positive results from its Phase II trials of...

  • R&D News Headlines January 15, 2003 - February 14, 2004.  // PharmaWatch: Biotechnology;March 2004, Vol. 3 Issue 3, p5 

    Reports developments related to the biotechnology industry in the U.S. as of March 2004. Initiation of clinical trials of Antegren rheumatoid arthritis candidate by Elan and Biogen Idec; Expansion of the Satraplatin phase III trial of GPC Biotech AG; Failure of Genentech's breast cancer drug...

  • American Society of Clinical Oncology.  // BioWorld Today;6/3/2009, Vol. 20 Issue 105, p5 

    The article highlights the Phase III Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial presented by GPC Biotech AG at the 2009 American Society of Clinical Oncology (ASCO) annual meeting. The trial compares satraplatin plus prednisone and placebo plus prednisone in patients...

  • GPC BIOTECH MARKETING AUTHORIZATION APPLICATION WITHDRAWN.  // Worldwide Biotech;Sep2008, Vol. 20 Issue 9, p5 

    The article reports on the plan of GPC Biotech's partner for satraplatin in Europe to withdraw the Marketing Authorization Application (MAA) for the drug plus prednisone for the treatment of hormone-refractory prostate cancer patients. Such decision was based on a list of outstanding issues...

  • CLINICAL TRIALS NEWS.  // Applied Clinical Trials;Jun2006, Vol. 15 Issue 6, p16 

    The article offers information regarding clinical trials conducted by some pharmaceutical companies in the U.S. Sonus Pharmaceuticals Inc. reported that one of their breast cancer patients, who maintains TOCOSOL paclitaxel intake, was well on track. Meanwhile, Advaxis Inc. has treated its first...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics